Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that the Research Council of Norway has approved Lytix’s application for up to NOK14.3m (US$1.3m) of non-dilutive financial support from the ‘SkatteFUNN’ R&D tax incentive scheme for a project in respect of its lead […]
Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract for a poster presentation at the ESMO Congress 2023 today has been published online on the ESMO website. After the submission of the abstract, the data set to be included in […]
Oslo, 9 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Henrik Jespersen, Head of Melanoma Oncology at Oslo University Hospital, will give a presentation of the NeoLIPA trial with LTX-315 at the 15th Nordic Melanoma Meeting (Reykjavik, 11-13 October 2023). The title […]
